Intelligence Feed event · Equity · 2026-09-12

    Cellectis sets September 14 business update on CAR-T and gene editing pipeline

    Question

    Cellectis sets September 14 business update on CAR-T and gene editing pipeline

    Direct answer

    Clinical-stage biotechnology firm Cellectis will provide an operational and clinical overview on September 14, 2026. The update will detail ongoing clinical trial progress in allogeneic CAR-T candidates and gene editing applications. Investors will monitor trial enrollment velocity, partnered asset timelines, and liquidity metrics supporting clinical progression.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Cellectis sets September 14 business update on CAR-T and gene editing pipeline”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/cellectis-sets-september-14-business-update-on-car-t-and-gene-editing-pipeline-feb11b

    EQUITY
    Cellectis sets September 14 business update on CAR-T and gene editing pipeline
    Clinical-stage biotechnology firm Cellectis will provide an operational and clinical overview on September 14, 2026. The update will detail ongoing clinical trial progress in allogeneic CAR-T candidates and gene editing applications. Investors will monitor trial enrollment velocity, partnered asset timelines, and liquidity metrics supporting clinical progression.
    CLLS
    Impact
    55
    SEP 12
    SIG
    85%
    CLLS
    Cellectis sets September 14 business update on CAR-T and gene editing pipeline
    Clinical-stage biotechnology firm Cellectis will provide an operational and clinical overview on September 14, 2026. The update will detail ongoing clinical trial progress in allogeneic CAR-T candidates and gene editing applications. Investors will monitor trial enrollment velocity, partnered asset timelines, and liquidity metrics supporting clinical progression.
    → Clinical development milestones and pipeline financing updates directly determine CLLS cash runway valuation and partner milestones.
    Impact
    Clinical-stage biotechnology firm Cellectis will provide an operational and clinical overview on September 14, 2026. The update will detail ongoing clinical trial progress in allogeneic CAR-T candidates and gene editing applications. Investors will monitor trial enrollment velocity, partnered asset timelines, and liquidity metrics supporting clinical progression.
    Affected
    CLLS
    Transmission
    Clinical development milestones and pipeline financing updates directly determine CLLS cash runway valuation and partner milestones.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CLLSclinical pipeline progress disclosure impacting biotech valuationWatchintradayCellectis hosting conference call and webcast on September 14 to provide business update.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month